Personal

Ticket to Biotech

No refunds will be administered. Be sure that you're an accepted T2B member before paying for your ticket.

***If you do not receive your event confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the Zoom info and cal invite.***

If you're not part of Ticket to Biotech, 

, and join before registering for this event:

Every consequential communications decision carries multiple forms of risk: A position that reassures employees may create political exposure. Silence that protects the company legally may weaken trust with patients or customers. A quick response may satisfy one stakeholder while limiting the company’s options later. Communicators are often the ones helping leadership see those tradeoffs clearly. Yet many organizations still evaluate reputational, legal, commercial, employee, investor, and policy risk in separate conversations, or default to whichever concern has the strongest internal advocate. This Comm Convo will examine how senior communicators can bring those perspectives together, clarify the organization’s risk appetite, and help leaders make defensible choices when every available path carries consequences.

Ethan Lovell, MBA, Senior Director of Investor Relations, Formerly Avidity Biosciences

 is a biotechnology investor relations professional and former institutional investor with three decades of experience spanning biopharmaceutical equity research, portfolio management, corporate communications, and capital markets strategy. Most recently, Ethan served as Senior Director of Investor Relations at Avidity Biosciences, which was acquired by Novartis. Previously, Ethan served as Head of Investor Relations at Theravance Biopharma and Chief External Affairs & Communications Officer at Agenus.

Before his career in investor relations, Ethan spent more than two decades on Wall Street, including 12 years at Janus Henderson Investors as a healthcare analyst and portfolio manager, where he co-managed the $10 billion Global Life Sciences strategy. He also held investment positions at ClearBridge Investments, Saranac Capital Management, and Bear Stearns. Ethan combines experience in corporate communications and investor relations with firsthand knowledge of how institutional investors evaluate companies, allocate capital and manage risk.

He holds an MBA from Tulane University, an MA from the University of Denver, and a bachelor's degree in chemistry from Bowdoin College.

Lisa Popyk, Communications Strategy Consultant, Writing Unlimited (Moderator)

Chrissy Trank, Senior Director, Oncology Drug Development Communications, Bristol Myers Squibb

 is a strategic healthcare communications leader with more than 20 years of experience spanning oncology, hematology, vaccines, R&amp;D and commercial communications. As Senior Director, Oncology Drug Development Communications at Bristol Myers Squibb, she leads worldwide communications for the oncology and hematology clinical-development pipeline, shaping portfolio and data narratives and leading integrated communications for major medical congresses.

Previously, Chrissy held senior communications roles at Merck and Bristol-Myers Squibb, leading communications for major product launches, scientific and regulatory milestones, disease- awareness initiatives and executive thought leadership. She began her career at Deborah Heart and Lung Center, where she held roles in public relations and practice development. She holds an MBA in Marketing from Drexel University and a BA in English/Professional Writing from Elizabethtown College. She also proudly holds a seat on the Elizabethtown College Alumni Council.

Outside of work, Chrissy is proud (and loud!) football mom, animal rescuer and aspiring pickleballer.

T2B October Comm Convo: The Comms Risk Recalculation